No trading signal; this is a mandatory initial filing, not a new purchase or sale. Monitor for future Form 4 filings to detect actual insider transactions. Vesting of over 573,000 restricted shares in 2027 could create downward pressure if sold en masse.
Price Chart
Executive Summary
Or Eisenberg, CFO of NeuroSense Therapeutics, filed a Form 3 disclosing beneficial ownership of 1,054,050 ordinary shares, including 21,000 from fully vested options and 66,666 from a 2024 private placement, plus warrants for 66,666 shares. The filing is routine and reflects existing holdings, not new transactions.
Key Facts
- Or Eisenberg, CFO of NeuroSense Therapeutics, filed initial beneficial ownership report (Form 3) as required under Section 16.
- Reports beneficial ownership of 1,054,050 ordinary shares, consisting of direct and indirect holdings via a trustee for tax purposes under Israeli law.
- Includes 21,000 shares underlying fully vested options and 66,666 shares acquired in a private placement on August 15, 2024, at $0.75 per share.
- Holds warrants to purchase an additional 66,666 shares, exercisable at $0.75, expiring 2029.
- 573,126 restricted shares are set to vest in two tranches: 75% on April 16, 2027, and the remainder on October 16, 2027, subject to continued service or acceleration upon a business milestone.
Financial Impact
No immediate financial impact — disclosure of pre-existing holdings. Potential future dilution of up to 133,332 shares if all options and warrants are exercised.
Risk Factors
- Potential share price dilution if options and warrants are exercised, especially given the company's small $7M market cap.
- Concentration risk: CFO holds a significant portion of outstanding shares, increasing sensitivity to insider sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-038542 |
| Document: 0001213900-26-038542-index.html | 0001213900-26-038542 |
| Document: 0001213900-26-038542.txt | 0001213900-26-038542 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $0.1451 $0.0500 | ▼ −65.54% | ▼ −69.35% | — |
Jun 8, 2026 20w ago | 6-K | $0.1500 $0.0456 | ▼ −69.60% | ▼ −72.65% | — |
Apr 28, 2026 26w ago | 6-K | $0.2080 $0.0601 | ▼ −71.11% | ▼ −75.10% | — |
Apr 24, 2026 26w ago | 6-K | $0.2080 $0.0811 | ▼ −61.01% | ▼ −66.09% | — |
Apr 6, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▼ −64.76% | ▼ −78.23% | — |
Apr 3, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▲ +64.76% | ▲ +78.23% | — |
Apr 1, 2026 29w ago | 3 | $0.2080 $0.0630 | ▼ −69.71% | ▼ −83.87% | — |
Mar 31, 2026 30w ago | 20-F / 6-K | $0.2080 $0.2080 | · 0.00% | ▼ −13.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers